These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33011255)

  • 21. Stabilizing supersaturated drug-delivery system through mechanism of nucleation and crystal growth inhibition of drugs.
    Joshi P; Sangamwar AT
    Ther Deliv; 2018 Nov; 9(12):873-885. PubMed ID: 30444454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Probing the Interplay between Amorphous Solid Dispersion Stability and Polymer Functionality.
    Frank DS; Matzger AJ
    Mol Pharm; 2018 Jul; 15(7):2714-2720. PubMed ID: 29924614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of Phase Separation Propensity for Amorphous Spray Dried Dispersions.
    McNamara D; Yin S; Pan D; Crull G; Timmins P; Vig B
    Mol Pharm; 2017 Feb; 14(2):377-385. PubMed ID: 28068097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Mechanistic Model for Predicting the Physical Stability of Amorphous Solid Dispersions.
    Ojo AT; Lee PI
    J Pharm Sci; 2021 Apr; 110(4):1495-1512. PubMed ID: 32818440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs.
    Baghel S; Cathcart H; O'Reilly NJ
    J Pharm Sci; 2016 Sep; 105(9):2527-2544. PubMed ID: 26886314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent Advances in Understanding the Micro- and Nanoscale Phenomena of Amorphous Solid Dispersions.
    Ricarte RG; Van Zee NJ; Li Z; Johnson LM; Lodge TP; Hillmyer MA
    Mol Pharm; 2019 Oct; 16(10):4089-4103. PubMed ID: 31487183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of crystal nucleation and growth by water-soluble polymers and its impact on the supersaturation profiles of amorphous drugs.
    Ozaki S; Kushida I; Yamashita T; Hasebe T; Shirai O; Kano K
    J Pharm Sci; 2013 Jul; 102(7):2273-81. PubMed ID: 23658029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Crystal Nuclei on Dissolution of Amorphous Drugs.
    Yao X; Yu L; Zhang GGZ
    Mol Pharm; 2023 Mar; 20(3):1796-1805. PubMed ID: 36749110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutual Impact of Phase Separation/Crystallization and Water Sorption in Amorphous Solid Dispersions.
    Luebbert C; Wessner M; Sadowski G
    Mol Pharm; 2018 Feb; 15(2):669-678. PubMed ID: 29309155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crystallization of amorphous indomethacin during dissolution: effect of processing and annealing.
    Greco K; Bogner R
    Mol Pharm; 2010 Oct; 7(5):1406-18. PubMed ID: 20459092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amorphous-Amorphous Phase Separation in API/Polymer Formulations.
    Luebbert C; Huxoll F; Sadowski G
    Molecules; 2017 Feb; 22(2):. PubMed ID: 28212300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solution-mediated phase transformation: significance during dissolution and implications for bioavailability.
    Greco K; Bogner R
    J Pharm Sci; 2012 Sep; 101(9):2996-3018. PubMed ID: 22213419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Co amorphous systems: A product development perspective.
    Chavan RB; Thipparaboina R; Kumar D; Shastri NR
    Int J Pharm; 2016 Dec; 515(1-2):403-415. PubMed ID: 27771485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amorphous solid dispersions: a robust platform to address bioavailability challenges.
    Newman A; Nagapudi K; Wenslow R
    Ther Deliv; 2015 Feb; 6(2):247-61. PubMed ID: 25690090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation and correlation of physical stability, dissolution behaviour and interaction parameter of amorphous solid dispersions of telmisartan: a drug development perspective.
    Dukeck R; Sieger P; Karmwar P
    Eur J Pharm Sci; 2013 Jul; 49(4):723-31. PubMed ID: 23684913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Moisture-Induced Amorphous Phase Separation of Amorphous Solid Dispersions: Molecular Mechanism, Microstructure, and Its Impact on Dissolution Performance.
    Chen H; Pui Y; Liu C; Chen Z; Su CC; Hageman M; Hussain M; Haskell R; Stefanski K; Foster K; Gudmundsson O; Qian F
    J Pharm Sci; 2018 Jan; 107(1):317-326. PubMed ID: 29107047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A fast and reliable empirical approach for estimating solubility of crystalline drugs in polymers for hot melt extrusion formulations.
    Kyeremateng SO; Pudlas M; Woehrle GH
    J Pharm Sci; 2014 Sep; 103(9):2847-2858. PubMed ID: 24634063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pairwise polymer blends for oral drug delivery.
    Marks JA; Wegiel LA; Taylor LS; Edgar KJ
    J Pharm Sci; 2014 Sep; 103(9):2871-2883. PubMed ID: 24823790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct measurement of molecular mobility and crystallisation of amorphous pharmaceuticals using terahertz spectroscopy.
    Sibik J; Zeitler JA
    Adv Drug Deliv Rev; 2016 May; 100():147-57. PubMed ID: 26772139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.